Does 7-OH Show Up on a Drug Test? 7-Hydroxymitragynine and Kratom Screening

7-hydroxymitragynine, usually shortened to 7-OH, is the kratom derived alkaloid now sold as concentrated tablets, gummies, drink shots, and vape products in smoke shops, gas stations, and online. Because it is marketed near energy drinks and kava shots rather than as a controlled opioid, many employees and employers assume it either will not show up on a drug test at all, or will trigger the same result as a prescription opioid. Neither assumption is reliable. Standard workplace urine panels, including the extended opiate and oxycodone screens most employers use, are built around specific analytes and generally do not target mitragynine or 7-hydroxymitragynine. Detecting 7-OH use requires a test that is specifically designed and validated for kratom alkaloids, and confirming it requires laboratory chromatography. This article explains what 7-OH is, why most panels miss it, what specialty testing exists, and where the legal and regulatory status currently stands.

What is 7-OH (7-hydroxymitragynine)?

Kratom comes from the leaves of Mitragyna speciosa, a tree grown in Southeast Asia. According to the Drug Enforcement Administration's Diversion Control Division, kratom leaves contain dozens of alkaloids, but the two most studied are mitragynine, which makes up roughly two thirds of the total alkaloid content, and 7-hydroxymitragynine, which naturally occurs at less than 2 percent of total alkaloid content in raw leaf. See the DEA's kratom drug and chemical fact sheet. The U.S. Food and Drug Administration describes 7-OH as demonstrating substantially greater activity at the mu opioid receptor than mitragynine or even morphine, which is why concentrated 7-OH products behave differently in the body than chewing or brewing raw kratom leaf. Background on this distinction is available on the FDA's FDA and kratom public health page. The National Institute on Drug Abuse also notes that when a person ingests mitragynine, some of it converts to 7-hydroxymitragynine in the body, which is one reason the two alkaloids are studied together. See the NIDA kratom drug facts page.

What is sold today as a 7-OH product is not the same thing as chewing kratom leaf. Manufacturers extract and concentrate the alkaloid well above what occurs naturally, producing a much higher dose in a single tablet, gummy, or shot. The FDA has described this shift in its public health notice on 7-OH products marketed to consumers, which discusses how concentrated 7-OH items are packaged and sold alongside supplements and convenience store beverages rather than as opioids.

Does a standard drug test panel detect 7-OH?

Generally no. The federal five panel and most extended workplace panels are built around specific opiate and opioid analytes, such as morphine, codeine, and their metabolites on a standard opiate line, and oxycodone or oxymorphone on an expanded OXY line. Mitragynine and 7-hydroxymitragynine are structurally distinct indole alkaloids, not derivatives of the opium poppy, so an immunoassay antibody built to recognize morphine type molecules does not reliably cross react with kratom alkaloids. The NCBI Bookshelf overview of how immunoassay drug screening panels are built and what they are designed to catch is a useful primer, available at the StatPearls chapter on drug testing. A standard 5, 10, or 12 panel cup, and a standard opiate or expanded opioid immunoassay, will typically report negative for a person who has only used kratom or a 7-OH product, even at a high dose, unless the panel includes an assay specifically validated for kratom alkaloids.

Specialty immunoassays and lab confirmation

Because kratom and concentrated 7-OH use has grown, laboratory researchers have developed antibody based screening methods aimed specifically at mitragynine and related alkaloids, separate from standard opioid panels. Published research on building and validating these assays, including antibody development for detecting mitragynine in human urine, is indexed on PubMed Central. These specialty immunoassays are not part of a typical pre-employment or random workplace cup and generally have to be ordered specifically, either as a standalone kratom screen or as an add-on panel, when an employer or clinic has a documented reason to test for it. As with any immunoassay, a specialty kratom screen is presumptive rather than final. A laboratory confirmation using liquid chromatography tandem mass spectrometry (LC-MS/MS) is the method that identifies and quantifies mitragynine or 7-hydroxymitragynine specifically, and it is the step that should occur before any result is treated as verified.

Legal status of 7-OH and kratom

Kratom itself is not currently a controlled substance or listed chemical under the federal Controlled Substances Act, according to the DEA's fact sheet linked above. Concentrated 7-OH products are being treated differently by federal regulators. In July 2025 the FDA announced it was recommending that the Drug Enforcement Administration schedule concentrated 7-OH products under the Controlled Substances Act, while stating that the recommendation targets concentrated 7-OH, not natural kratom leaf. That announcement is available in the FDA press release FDA takes steps to restrict 7-OH opioid products. The DEA has final authority on scheduling, and any scheduling action requires a rulemaking process that includes a public comment period before it can be finalized. The FDA has separately issued warning letters to companies marketing 7-OH tablets, gummies, drink mixes, and shots, stating that 7-OH is not lawful in dietary supplements and cannot be lawfully added to conventional foods, and that no drug carrying FDA approval currently contains 7-OH. See the FDA warning letter announcement.

Separately from federal action, a number of states and some local jurisdictions have passed their own restrictions on kratom or on concentrated 7-OH products specifically, and these rules vary and continue to change. Employers and employees should not assume a product is legal everywhere it is sold, and should check current state and local law rather than relying on federal status alone.

What employers should consider

• A standard federal five panel or a typical extended workplace panel, including one with an oxycodone or expanded opioid line, is not built to detect kratom alkaloids and will generally not flag 7-OH use.
• If a workplace has a documented reason to screen for kratom or 7-OH, such as a safety incident or a specific policy concern, that requires ordering a specialty immunoassay or a laboratory panel that specifically includes mitragynine and 7-hydroxymitragynine, not a standard cup.
• Any presumptive positive on a specialty kratom screen should go through the same laboratory confirmation and medical review officer process used for any other drug class before it is treated as a verified result.
• Because federal scheduling of concentrated 7-OH is still moving through a rulemaking process, and because state and local rules vary, employers should build written policy language around current law rather than around news coverage of proposed scheduling, and should update that language as the regulatory picture develops.
• Employers should apply testing and disciplinary policy consistently and consult qualified counsel on how kratom and 7-OH fit into an existing drug free workplace policy.

For a broader look at how kratom itself interacts with standard workplace testing, see our related post on whether kratom shows up on a drug test. Concentrated 7-OH is part of a wider pattern of substances sold through convenience outlets that standard panels were not designed around, a pattern we also cover in our post on tianeptine and the gap in standard opioid panels.

Frequently asked questions

Does 7-OH show up on a standard 5 or 10 panel drug test?

Generally no. Standard panels are built around specific opiate and opioid analytes such as morphine and oxycodone, and mitragynine and 7-hydroxymitragynine are structurally different alkaloids that these immunoassays are not designed to catch.

Will 7-OH show up as a positive opiate or morphine result?

Not reliably. Because 7-hydroxymitragynine is not chemically an opium derivative, it does not consistently cross react with immunoassays built around morphine type molecules on a standard opiate line.

Is there a test that specifically detects 7-OH or kratom?

Yes. Laboratories can run a specialty immunoassay screen validated for mitragynine or 7-hydroxymitragynine, and confirm a presumptive result with LC-MS/MS. These are ordered specifically and are not part of a typical standard workplace cup.

Is 7-OH legal?

Natural kratom leaf is not a controlled substance under the federal Controlled Substances Act. The FDA has recommended that the DEA schedule concentrated 7-OH products, a recommendation the DEA is reviewing through its rulemaking process, and a number of states and localities have their own separate restrictions. The legal status varies and continues to change.

Should employers add a kratom or 7-OH screen to their standard panel?

That depends on the workplace's risk profile and policy goals. Because standard panels do not catch 7-OH, an employer that wants to screen for it needs to specifically add a validated kratom alkaloid test, and should apply that decision consistently and document it in written policy.

Does a positive kratom or 7-OH screen mean the result is confirmed?

No. Like any immunoassay, a specialty kratom or 7-OH screen is presumptive. A laboratory confirmation using chromatography and mass spectrometry, reviewed through the standard medical review officer process, is required before a result should be treated as verified.

Employers that need to build or expand a testing program around emerging substances like 7-OH can review our drug test cup collection and talk with our lab partners about adding a specialty confirmation panel where policy requires it.

This article is general information, not legal or medical advice. Panel configurations, laboratory offerings, and state and local law on kratom and 7-OH vary and continue to change, and employers and employees should consult qualified counsel and a medical review officer for specific cases.